Lisanti Capital Growth LLC lowered its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 51.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,430 shares of the biotechnology company's stock after selling 27,015 shares during the quarter. Lisanti Capital Growth LLC owned approximately 0.05% of Vericel worth $1,396,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Vericel during the 4th quarter valued at approximately $28,126,000. Arizona State Retirement System grew its stake in Vericel by 6.7% during the fourth quarter. Arizona State Retirement System now owns 14,192 shares of the biotechnology company's stock valued at $779,000 after acquiring an additional 897 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in Vericel in the 4th quarter valued at $956,000. Atria Investments Inc lifted its stake in Vericel by 2.4% in the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company's stock worth $437,000 after purchasing an additional 184 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Vericel by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 451,464 shares of the biotechnology company's stock valued at $24,790,000 after purchasing an additional 17,258 shares during the last quarter.
Vericel Stock Down 2.1 %
VCEL traded down $1.04 during trading on Tuesday, reaching $47.81. The company had a trading volume of 343,397 shares, compared to its average volume of 420,724. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The stock has a market cap of $2.39 billion, a P/E ratio of 796.97 and a beta of 1.78. The business has a 50 day simple moving average of $56.35 and a 200-day simple moving average of $51.99.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. Truist Financial reaffirmed a "buy" rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a report on Saturday. Stephens reiterated an "overweight" rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. Finally, Canaccord Genuity Group upped their price target on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Vericel presently has an average rating of "Moderate Buy" and an average target price of $62.29.
Read Our Latest Stock Report on Vericel
Insiders Place Their Bets
In other news, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Siegal sold 1,092 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the transaction, the insider now directly owns 1,206 shares in the company, valued at $74,759.94. This represents a 47.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,500 shares of company stock valued at $466,200 over the last 90 days. Insiders own 5.20% of the company's stock.
Vericel Profile
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
See Also
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
